search
Back to results

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

Primary Purpose

Hand, Foot and Mouth Disease

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Concomitant administration of EV71 vaccine with EPI vaccines
Single injection of EPI vaccine
EV71 Vaccine only
Sponsored by
Sinovac Biotech Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hand, Foot and Mouth Disease focused on measuring Inactivated Enterovirus Type 71 (EV71) Vaccine, Concomitant vaccination, Safety, Immunogenicity, Infant

Eligibility Criteria

6 Months - 6 Months (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy volunteers aged 6 months
  • Finished two doses of vaccination (0,1 month) of hepatitis B vaccine prior to study entry
  • Proven legal identity
  • Guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study

Exclusion Criteria:

  • Finished all the three doses vaccination (0,1,6 month) of hepatitis B vaccine prior to study entry
  • Prior vaccination of meningococcal polysaccharide vaccine
  • Prior vaccination of EV71 vaccine
  • Unable to receive vaccination on both arms
  • History of hand foot and mouth disease
  • Previously tested HBsAg positive
  • Mother of the subject had been previously tested HBsAg positive
  • History of asthma; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc
  • Congenital malformation, developmental disorders, genetic defects
  • Autoimmune disease or immunodeficiency/immunosuppressive
  • Severe nervous system disease or mental illness
  • Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders
  • Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry
  • Receipt of blood product (e.g., immunoglobulin) within 3 months prior to study entry
  • Receipt of any other investigational medicine(s) within 30 days prior to study entry
  • Receipt of any live attenuated vaccine within 14 days prior to study entry
  • Receipt of any subunit vaccine or inactivated vaccine within 7 days prior to study entry
  • Acute disease or acute stage of chronic disease within 7 days prior to study entry
  • Axillary temperature > 37.0 ℃
  • Any other factor that suggesting the volunteer is unsuitable for this study based on the judgement of investigators

Exclusion Criteria of the Second Injection:

  • Subjects with one of the following 1 to 3 conditions are forbidden to continue vaccination, while the other study steps could be carried out based on the judgement of investigator; for subjects with one of the following 4 to 5 conditions, whether to continue vaccination are determined by the investigator; for subjects with one of the following 6 to 7 conditions, vaccination may be delayed in the time window specified in the study:

    1. Any serious adverse event that has a causal relationship with the investigated vaccine (except the group II)
    2. Severe allergic reactions or hypersensitivity after vaccination (including urticaria / rash appear within 30 minutes after vaccination, except the group II )
    3. Any confirmed or suspected autoimmune disease or immunodeficiency disease (e.g., HIV infection)
    4. New chronic diseases or acute stage of chronic diseases
    5. Other reactions (including severe pain, severe swelling, severe activity limitation, persistent hyperthermia, severe headache or other systemic or local reactions) determined by the investigators
    6. Acute diseases (moderate or severe diseases with or without fever)
    7. Axillary temperature> 37.0 ℃

Sites / Locations

  • Dongguan Municipal Center for Disease Control and Prevention

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

Group I-EV71 vaccine and EPI vaccines

Group II-EPI vaccine only

Group III-EV71 vaccine only

Arm Description

Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine(intramuscular injection,0.5ml)on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.

Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.

EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.

Outcomes

Primary Outcome Measures

The seropositive rate of EV71 neutralizing antibody, anti-HBs and serum bactericidal antibody 1 month after 2 doses of vaccination
Immunogenicity indicator

Secondary Outcome Measures

Incidence of solicited local or systemic adverse events within 7 days after each dose
Safety indicator
Incidence of unsolicited local or systemic adverse events within 30 days after each dose
Safety indicator
Incidence of serious adverse events during the period of safety monitoring
Safety indicator
The seroconversion rate of EV71 neutralizing antibody, anti-HBs and serum bactericidal antibody(SBA) 1 month after 2 doses of vaccination
Immunogenicity indicator
EV71 neutralizing antibody GMT, anti-HBs GMC and SBA antibody GMT 1 month after 2 doses of vaccination
Immunogenicity indicator

Full Information

First Posted
September 4, 2017
Last Updated
July 26, 2021
Sponsor
Sinovac Biotech Co., Ltd
Collaborators
Guangdong Center for Disease Prevention and Control
search

1. Study Identification

Unique Protocol Identification Number
NCT03274102
Brief Title
Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines
Official Title
A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
April 22, 2017 (Actual)
Primary Completion Date
November 1, 2017 (Actual)
Study Completion Date
November 1, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sinovac Biotech Co., Ltd
Collaborators
Guangdong Center for Disease Prevention and Control

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine.
Detailed Description
This study is an open-label, single-center, randomized, comparative phase IV clinical trial. The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine manufactured by Sinovac (Beijing) Vaccine Technology Co., Ltd. with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine. 780 healthy infants of 6 months old as participants are randomly assigned into three experimental groups in the ratio 1:1:1. The group I receive EV71 Vaccine (first dose)& recombinant hepatitis B vaccine on day 0 and EV71 vaccine (second dose)& Group A meningococcal polysaccharide vaccine on day 30. The group II receive recombinant hepatitis B vaccine on day 0 and Group A meningococcal polysaccharide vaccine on day 30. The group III receive the first and second dose of EV71 Vaccine on day 0 and day 30 respectively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hand, Foot and Mouth Disease
Keywords
Inactivated Enterovirus Type 71 (EV71) Vaccine, Concomitant vaccination, Safety, Immunogenicity, Infant

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Masking Description
open-labelled
Allocation
Randomized
Enrollment
780 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group I-EV71 vaccine and EPI vaccines
Arm Type
Experimental
Arm Description
Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine(intramuscular injection,0.5ml)on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.
Arm Title
Group II-EPI vaccine only
Arm Type
Active Comparator
Arm Description
Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.
Arm Title
Group III-EV71 vaccine only
Arm Type
Active Comparator
Arm Description
EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.
Intervention Type
Biological
Intervention Name(s)
Concomitant administration of EV71 vaccine with EPI vaccines
Intervention Description
The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.; the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study
Intervention Type
Biological
Intervention Name(s)
Single injection of EPI vaccine
Intervention Description
The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study
Intervention Type
Biological
Intervention Name(s)
EV71 Vaccine only
Intervention Description
The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
Primary Outcome Measure Information:
Title
The seropositive rate of EV71 neutralizing antibody, anti-HBs and serum bactericidal antibody 1 month after 2 doses of vaccination
Description
Immunogenicity indicator
Time Frame
30 days after 2 doses of injection
Secondary Outcome Measure Information:
Title
Incidence of solicited local or systemic adverse events within 7 days after each dose
Description
Safety indicator
Time Frame
7 days after each dose of injection
Title
Incidence of unsolicited local or systemic adverse events within 30 days after each dose
Description
Safety indicator
Time Frame
30 days after each dose of injection
Title
Incidence of serious adverse events during the period of safety monitoring
Description
Safety indicator
Time Frame
60 days after the first dose injection
Title
The seroconversion rate of EV71 neutralizing antibody, anti-HBs and serum bactericidal antibody(SBA) 1 month after 2 doses of vaccination
Description
Immunogenicity indicator
Time Frame
30 days after 2 doses of injection
Title
EV71 neutralizing antibody GMT, anti-HBs GMC and SBA antibody GMT 1 month after 2 doses of vaccination
Description
Immunogenicity indicator
Time Frame
30 days after 2 doses of injection

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
6 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy volunteers aged 6 months Finished two doses of vaccination (0,1 month) of hepatitis B vaccine prior to study entry Proven legal identity Guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study Exclusion Criteria: Finished all the three doses vaccination (0,1,6 month) of hepatitis B vaccine prior to study entry Prior vaccination of meningococcal polysaccharide vaccine Prior vaccination of EV71 vaccine Unable to receive vaccination on both arms History of hand foot and mouth disease Previously tested HBsAg positive Mother of the subject had been previously tested HBsAg positive History of asthma; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc Congenital malformation, developmental disorders, genetic defects Autoimmune disease or immunodeficiency/immunosuppressive Severe nervous system disease or mental illness Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry Receipt of blood product (e.g., immunoglobulin) within 3 months prior to study entry Receipt of any other investigational medicine(s) within 30 days prior to study entry Receipt of any live attenuated vaccine within 14 days prior to study entry Receipt of any subunit vaccine or inactivated vaccine within 7 days prior to study entry Acute disease or acute stage of chronic disease within 7 days prior to study entry Axillary temperature > 37.0 ℃ Any other factor that suggesting the volunteer is unsuitable for this study based on the judgement of investigators Exclusion Criteria of the Second Injection: Subjects with one of the following 1 to 3 conditions are forbidden to continue vaccination, while the other study steps could be carried out based on the judgement of investigator; for subjects with one of the following 4 to 5 conditions, whether to continue vaccination are determined by the investigator; for subjects with one of the following 6 to 7 conditions, vaccination may be delayed in the time window specified in the study: Any serious adverse event that has a causal relationship with the investigated vaccine (except the group II) Severe allergic reactions or hypersensitivity after vaccination (including urticaria / rash appear within 30 minutes after vaccination, except the group II ) Any confirmed or suspected autoimmune disease or immunodeficiency disease (e.g., HIV infection) New chronic diseases or acute stage of chronic diseases Other reactions (including severe pain, severe swelling, severe activity limitation, persistent hyperthermia, severe headache or other systemic or local reactions) determined by the investigators Acute diseases (moderate or severe diseases with or without fever) Axillary temperature> 37.0 ℃
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Huizhen Zheng
Organizational Affiliation
Guangdong Center for Disease Prevention and Control
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dongguan Municipal Center for Disease Control and Prevention
City
Dongguan
State/Province
Guangdong
ZIP/Postal Code
523129
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
30891604
Citation
Zhang Z, Liang Z, Zeng J, Zhang J, He P, Su J, Zeng Y, Fan R, Zhao D, Ma W, Zeng G, Zhang Q, Zheng H. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial. J Infect Dis. 2019 Jul 2;220(3):392-399. doi: 10.1093/infdis/jiz129.
Results Reference
derived

Learn more about this trial

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

We'll reach out to this number within 24 hrs